<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>12</volume><submitter>Hume-Nixon M</submitter><pubmed_abstract>&lt;h4>Background&lt;/h4>Pneumonia is a major cause of death in children aged under five years. As children with severe pneumonia have the highest risk of morbidity and mortality, previous studies have evaluated the additional benefit of adjunctive treatments such as oseltamivir, oral steroids, macrolides, and vitamin supplementation that can be added to standard antibiotic management to improve clinical outcomes. The study reviewed the evidence for the role of these additional treatments for children with severe pneumonia in low- and middle-income countries (LMICs).&lt;h4>Methods&lt;/h4>Four electronic databases were searched for English-language articles between 2000 to 2020. Systematic reviews (SRs) with meta-analyses, comparative cohort studies, and randomised controlled trials (RCTs) from LMICs t</pubmed_abstract><journal>Journal of global health</journal><pagination>10005</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9393748</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Review of the role of additional treatments including oseltamivir, oral steroids, macrolides, and vitamin supplementation for children with severe pneumonia in low- and middle-income countries.</pubmed_title><pmcid>PMC9393748</pmcid><pubmed_authors>Graham H</pubmed_authors><pubmed_authors>Mulholland K</pubmed_authors><pubmed_authors>von Mollendorf C</pubmed_authors><pubmed_authors>Were W</pubmed_authors><pubmed_authors>Chua P</pubmed_authors><pubmed_authors>Kevat P</pubmed_authors><pubmed_authors>Quach A</pubmed_authors><pubmed_authors>Simon J</pubmed_authors><pubmed_authors>Walker P</pubmed_authors><pubmed_authors>Russell F</pubmed_authors><pubmed_authors>ARI Review group</pubmed_authors><pubmed_authors>Neal E</pubmed_authors><pubmed_authors>Wilkes C</pubmed_authors><pubmed_authors>Reyburn R</pubmed_authors><pubmed_authors>Nisar YB</pubmed_authors><pubmed_authors>Duke T</pubmed_authors><pubmed_authors>Kazi S</pubmed_authors><pubmed_authors>Nguyen C</pubmed_authors><pubmed_authors>Gwee A</pubmed_authors><pubmed_authors>Graham S</pubmed_authors><pubmed_authors>Gray A</pubmed_authors><pubmed_authors>Hume-Nixon M</pubmed_authors><pubmed_authors>Ryan K</pubmed_authors></additional><is_claimable>false</is_claimable><name>Review of the role of additional treatments including oseltamivir, oral steroids, macrolides, and vitamin supplementation for children with severe pneumonia in low- and middle-income countries.</name><description>&lt;h4>Background&lt;/h4>Pneumonia is a major cause of death in children aged under five years. As children with severe pneumonia have the highest risk of morbidity and mortality, previous studies have evaluated the additional benefit of adjunctive treatments such as oseltamivir, oral steroids, macrolides, and vitamin supplementation that can be added to standard antibiotic management to improve clinical outcomes. The study reviewed the evidence for the role of these additional treatments for children with severe pneumonia in low- and middle-income countries (LMICs).&lt;h4>Methods&lt;/h4>Four electronic databases were searched for English-language articles between 2000 to 2020. Systematic reviews (SRs) with meta-analyses, comparative cohort studies, and randomised controlled trials (RCTs) from LMICs t</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Aug</publication><modification>2025-04-04T07:16:08.196Z</modification><creation>2025-02-18T23:49:01.864Z</creation></dates><accession>S-EPMC9393748</accession><cross_references><pubmed>35993199</pubmed><doi>10.7189/jogh.12.10005</doi></cross_references></HashMap>